Table 2.
Baseline clinical and immunological profile of adults living with HIV on ART at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia (n=848)
| Variables | Frequency (n) | Percentage |
| Baseline OIs | ||
| Yes | 339 | 39.9 |
| No | 509 | 60.1 |
| Baseline nutritional status | ||
| Underweight | 228 | 26.9 |
| Normal-weight | 620 | 73.1 |
| Functional status | ||
| Working | 707 | 83.4 |
| Ambulatory/bedridden | 141 | 16.6 |
| CD4 cell count | ||
| Severe immunodeficiency (CD4 <200 cells/mm3) | 406 | 63.6 |
| Mild immunodeficiency (CD4 ≥200 cells/mm3) | 232 | 36.4 |
| WHO clinical staging | ||
| Mild disease stage (stage I and II) | 612 | 72.2 |
| Advanced disease stage (stage III and IV) | 236 | 27.8 |
| Haemoglobin level | ||
| Anaemic | 164 | 20.6 |
| Non-anaemic | 634 | 79.4 |
| ART eligibility criteria | ||
| Immunological/clinical | 378 | 44.6 |
| Test and treat | 470 | 55.4 |
| Baseline ART regimens | ||
| Efavirenz base | 82 | 92.2 |
| Nevirapine or dolutegravir base | 66 | 7.8 |
ART, antiretroviral therapy; OI, opportunistic infection.